TDP-43 MODULATION BY CDC7 INHIBITORS AS A THERAPEUTIC STRATEGY FOR AMYOTROPHIC LATERAL SCLEROSIS

Elisa Rojas-Prats (1), Loreto Martinez-Gonzalez (1), Nicole Liachko (2), Brian Kraemer (2), Carmen Gil (1), Angeles Martin-Requero (1), Ana Martinez (1)

1) Centro de Investigaciones Biologicas (CIB-CSIC), C/Ramiro de Maeztu 9, 28040 Madrid, Spain
2) University of Washington, Psychiatry & Behavioral Sciences, Veterans Affairs Puget Sound Health Care System, 1660 South Columbian Way, 98108 Seattle, USA

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease characterized by loss of motor neurons, leading to muscle wasting and early death due to respiratory failure. Listed as a “rare disease”, ALS affects 2 to 3 people of every 100,000 citizens in Europe and North America. However, the etiology remains unknown and no effective treatment exists to date, thus the search for new drugs able to modulate this neurodegeneration is needed. Approximately, between 5 to 10% of ALS cases have a genetic link, while the sporadic ones represent 90% of all cases [1].

TDP-43 has been recognized to play a key role in the disease, in both familiar and sporadic cases. In normal conditions, TDP-43 is a nuclear protein and regulates the expression of many genes, but it’s hyperphosphorylated, ubiquitinated and N-terminally truncated in the cytoplasm of motor neurons in ALS patients [2].

Protein kinases are important targets for several neurodegenerative disorders, as well as inflammatory diseases, diabetes and cancer. The reason is that aberrant protein kinase signaling is implicated in many of these human diseases [3]. In this context, it has been recently discovered that cell division cycle kinase 7 (CDC7) is responsible for pathological TDP-43 phosphorylation [4]. So that, CDC7 inhibition by brain permeable small molecules will be a good strategy for the treatment of ALS, as they could strongly reduce TDP-43 phosphorylation, preventing TDP-43-dependent neurodegeneration.

In our laboratory, CDC7 inhibitors have been designed and synthesized showing a low micromolar activity against this kinase. Furthermore, these compounds were predicted as able to cross the blood brain barrier based on PAMPA assays and selective against other kinases. Here, we present the ability of these compounds to reduce TDP-43 phosphorylation both in vitro and in vivo in ALS models as well as restore its nuclear location. Additionally, this same behavior is observed when FTLD patient’s lymphoblasts are treated [5][6].

References
6) Martinez, A.; Gil, C.; Martin-Requero, A.; Rojas-Prats, E.; Martinez-Gonzalez, L., Derivados de purina inhibidores de CDC7 y su uso para el tratamiento de patologías neurológicas, P201830914.